Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
about
Virus-like particles production in green plantsInfluenza vaccines based on virus-like particlesHuman papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during HPV-16 semen infectionAn enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice.Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.Prevention of cancer by prophylactic human papillomavirus vaccines.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.Vaccines that facilitate antigen entry into dendritic cells.Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.Dendritic cells in viral pathogenesis: protective or defective?Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:CVirus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.Immunostimulatory colloidal delivery systems for cancer vaccines.Human papillomavirus capsids preferentially bind and infect tumor cells.A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose.Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.Virus-like particles for the prevention of human papillomavirus-associated malignancies.Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.Immunotherapeutic polyoma and human papilloma virus-like particles.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Understanding and learning from the success of prophylactic human papillomavirus vaccines.Developments in virus-like particle-based vaccines for HIV.VLPs and particle strategies for cancer vaccines.Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.Recombinant expression of beak and feather disease virus capsid protein and assembly of virus-like particles in Nicotiana benthamiana.Development of human papillomavirus chimaeric L1/L2 candidate vaccines.Explanations for the high potency of HPV prophylactic vaccines.
P2860
Q24650772-F8AAA071-C5BB-4AF3-92EE-27E3E801E316Q30376236-B0DBA69B-FCF6-4C3F-B337-716577520376Q30561339-82620657-FD91-4365-A0DB-7EE645ECD1D3Q31121276-A75EFE88-9CE4-4143-99A2-6E73F1C587C6Q33571959-6DA5742F-3699-43DB-AF98-30DE24F38B25Q33788885-C540C60E-1691-46AA-A751-20316E4F464FQ34005446-5C7F9F15-48E5-4614-A8C9-EF18DC3D47D5Q34054427-1A782D34-3233-418D-BD72-483976EFDBB5Q34762053-1B116F67-0690-406B-8D75-4573580C8336Q34786808-B7ED9895-CB3F-49A7-BD9D-6865008B13BBQ35915763-C20D4CA9-C676-4A34-A938-1FB5FC68D814Q36097134-A74DD842-E290-45F6-95FD-A5F118001274Q36207868-4401C20F-8C25-4584-A8FA-FEF7F2D25BDBQ36315857-13336D5E-7545-4C6A-B34E-B29D8C3D7546Q36383391-25B54327-06D0-4BDD-8810-2ECCED952F70Q36460849-C57758AC-58A2-44BB-83A4-3D9A6BEEA58DQ36470809-337D3DFC-4262-40C7-9C21-DA188EDAB58AQ36630332-307EA01C-38E0-4423-9245-9BF5541DC6C8Q36897382-DB4F8842-8FE6-4EA1-9110-39526222AEEDQ36987072-BE7B5A13-0362-484A-BBE0-3C75B1E0E314Q37328475-C7E4CC28-34E8-4301-9B1C-5E2644B3785CQ37568227-CC4611C3-9EAD-41EC-B9DC-B6B32515D142Q37773267-B4EFEEF1-94F1-455E-A7AA-26A67DE5952DQ37951525-C40E045F-1DC6-4105-A15C-E358F55D4130Q38041983-F550AE4A-09A0-459C-ACBD-22A6036D5F70Q38081965-7B0FF7E0-1EAC-4896-AB51-5F5E4657E911Q38152475-E0762C00-355F-47D0-B9C7-7DC121DFCAD6Q38879108-F9D49D6C-B324-48CE-AE65-76EB74F25E89Q40047200-03C38925-D82C-4834-9A89-0A85349D9B3DQ43493362-6D134C02-CCF5-4595-8211-D8F0A1B4D2ADQ47554977-05F4991A-8EEC-478C-BB86-61A8DF54AA1D
P2860
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Interaction of papillomavirus ...... loid antigen-presenting cells.
@en
Interaction of papillomavirus ...... loid antigen-presenting cells.
@nl
type
label
Interaction of papillomavirus ...... loid antigen-presenting cells.
@en
Interaction of papillomavirus ...... loid antigen-presenting cells.
@nl
prefLabel
Interaction of papillomavirus ...... loid antigen-presenting cells.
@en
Interaction of papillomavirus ...... loid antigen-presenting cells.
@nl
P2093
P1433
P1476
Interaction of papillomavirus ...... loid antigen-presenting cells.
@en
P2093
Cynthia D Thompson
Douglas R Lowy
John T Schiller
Patricia M Day
Petra Lenz
Silvia M Bacot
P304
P356
10.1016/S1521-6616(02)00039-6
P577
2003-03-01T00:00:00Z